These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6234277)

  • 1. Norfloxacin--a review of pharmacology and tissue penetration.
    Wise R
    J Antimicrob Chemother; 1984 May; 13 Suppl B():59-64. PubMed ID: 6234277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results.
    Hughes PJ; Webb DB; Asscher AW
    J Antimicrob Chemother; 1984 May; 13 Suppl B():55-7. PubMed ID: 6234276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and tissue penetration of norfloxacin.
    Adhami ZN; Wise R; Weston D; Crump B
    J Antimicrob Chemother; 1984 Jan; 13(1):87-92. PubMed ID: 6230344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and tissue penetration of enoxacin and norfloxacin.
    Wise R; Lockley R; Webberly M; Adhami ZN
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():75-81. PubMed ID: 6238932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic studies of norfloxacin in laboratory animals.
    Gilfillan EC; Pelak BA; Bland JA; Malatesta PF; Gadebusch HH
    Chemotherapy; 1984; 30(5):288-96. PubMed ID: 6237890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study.
    Reeves DS; Lacey RW; Mummery RV; Mahendra M; Bint AJ; Newsom SW
    J Antimicrob Chemother; 1984 May; 13 Suppl B():99-105. PubMed ID: 6234282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.
    Montay G; Goueffon Y; Roquet F
    Antimicrob Agents Chemother; 1984 Apr; 25(4):463-72. PubMed ID: 6587830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential usefulness of norfloxacin in the treatment of urinary tract infections.
    Norrby SR
    Eur J Clin Microbiol; 1983 Jun; 2(3):227-9. PubMed ID: 6224677
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of norfloxacin in renal failure.
    Fillastre JP; Hannedouche T; Leroy A; Humbert G
    J Antimicrob Chemother; 1984 Oct; 14(4):439. PubMed ID: 6238930
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative in vitro activity of norfloxacin and four other chemotherapeutics against urinary gram-negative isolates.
    Esposito S; Galante D; Pennucci C; Barba D; Limauro D; Scioli C
    Chemioterapia; 1984 Jun; 3(3):196-9. PubMed ID: 6241506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of quinoline carboxylic acid derivatives in the dog prostate.
    Jensen KM; Madsen PO
    Prostate; 1983; 4(4):407-14. PubMed ID: 6223287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections.
    Vogel R; Deaney NB; Round EM; VandenBurg MJ; Currie WJ
    J Antimicrob Chemother; 1984 May; 13 Suppl B():113-20. PubMed ID: 6234271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norfloxacin disposition after sequentially increasing oral doses.
    Swanson BN; Boppana VK; Vlasses PH; Rotmensch HH; Ferguson RK
    Antimicrob Agents Chemother; 1983 Feb; 23(2):284-8. PubMed ID: 6220672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norfloxacin--a new quinolone for urinary infection.
    J Antimicrob Chemother; 1984 May; 13 Suppl B():1-142. PubMed ID: 6234269
    [No Abstract]   [Full Text] [Related]  

  • 15. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.
    Duckworth GJ; Williams JD
    J Antimicrob Chemother; 1984 May; 13 Suppl B():33-8. PubMed ID: 6234273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Norfloxacin sensitivity of bacterial pathogens of urinary tract infections].
    Modde H
    Schweiz Rundsch Med Prax; 1985 Apr; 74(17):439-42. PubMed ID: 3159064
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmaceutical studies on hydrates of AM-715. Physical characteristics and intestinal absorption].
    Yuasa R; Imai J; Morikawa H; Kusajima H; Uchida H; Irikura T
    Yakugaku Zasshi; 1982 May; 102(5):469-76. PubMed ID: 6215479
    [No Abstract]   [Full Text] [Related]  

  • 18. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.
    Nakamura S; Kurobe N; Kashimoto S; Ohue T; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 Jul; 24(1):54-60. PubMed ID: 6226241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.
    Eandi M; Viano I; Di Nola F; Leone L; Genazzani E
    Eur J Clin Microbiol; 1983 Jun; 2(3):253-9. PubMed ID: 6224683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.